COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response.
COVID-19
SARS-CoV-2
disease-modifying therapy
multiple sclerosis
risk factors
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
06
11
2020
accepted:
07
12
2020
pubmed:
20
12
2020
medline:
22
9
2021
entrez:
19
12
2020
Statut:
ppublish
Résumé
Information regarding multiple sclerosis (MS) patients with the 2019 novel coronavirus disease (COVID-19) is scarce. The study objective was to describe the incidence and characteristics of MS patients with COVID-19, to identify susceptibility and severity risk factors and to assess the proportion of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologies according to disease-modifying treatments. This was a retrospective study of an MS cohort analysing data collected between February and May 2020. Cases were identified through an email survey and clinical visits. The relationship of demographic and MS characteristics with COVID-19 and of the disease-modifying treatments with SARS-CoV-2 serostatus were examined. Data from 48 suspected cases out of 758 valid respondents and from 45 COVID-19 cases identified through clinical visits were collected. Incidence was 6.3%. Nineteen (20.3%) patients were hospitalized and two (2.2%) died. Multivariable models determined that age (odds ratio [OR] per 10 years 0.53, 95% confidence interval [CI] 0.34-0.85), contact with a confirmed case (OR 197.02, 95% CI 56.36-688.79), residence in Barcelona (OR 2.23, 95% CI 1.03-4.80), MS duration (OR per 5 years 1.41, 95% CI 1.09-1.83) and time on anti-CD20 treatment (OR per 2 years 3.48, 95% CI 1.44-8.45) were independent factors for presenting COVID-19 and age (OR per 10 years 2.71, 95% CI 1.13-6.53) for a severe COVID-19. Out of the 79 (84.9%) with serological test, 45.6% generated antibodies, but only 17.6% of those on anti-CD20 therapies. Lymphopaenia or immunoglobulin levels did not relate to COVID-19. Multiple sclerosis patients present similar incidence, risk factors and outcomes for COVID-19 as the general population. Patients treated with an anti-CD20 therapy for a longer period of time might be at a higher risk of COVID-19 and less than 20% generate an antibody response. Only age was related to severity.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Information regarding multiple sclerosis (MS) patients with the 2019 novel coronavirus disease (COVID-19) is scarce. The study objective was to describe the incidence and characteristics of MS patients with COVID-19, to identify susceptibility and severity risk factors and to assess the proportion of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologies according to disease-modifying treatments.
METHODS
METHODS
This was a retrospective study of an MS cohort analysing data collected between February and May 2020. Cases were identified through an email survey and clinical visits. The relationship of demographic and MS characteristics with COVID-19 and of the disease-modifying treatments with SARS-CoV-2 serostatus were examined.
RESULTS
RESULTS
Data from 48 suspected cases out of 758 valid respondents and from 45 COVID-19 cases identified through clinical visits were collected. Incidence was 6.3%. Nineteen (20.3%) patients were hospitalized and two (2.2%) died. Multivariable models determined that age (odds ratio [OR] per 10 years 0.53, 95% confidence interval [CI] 0.34-0.85), contact with a confirmed case (OR 197.02, 95% CI 56.36-688.79), residence in Barcelona (OR 2.23, 95% CI 1.03-4.80), MS duration (OR per 5 years 1.41, 95% CI 1.09-1.83) and time on anti-CD20 treatment (OR per 2 years 3.48, 95% CI 1.44-8.45) were independent factors for presenting COVID-19 and age (OR per 10 years 2.71, 95% CI 1.13-6.53) for a severe COVID-19. Out of the 79 (84.9%) with serological test, 45.6% generated antibodies, but only 17.6% of those on anti-CD20 therapies. Lymphopaenia or immunoglobulin levels did not relate to COVID-19.
CONCLUSIONS
CONCLUSIONS
Multiple sclerosis patients present similar incidence, risk factors and outcomes for COVID-19 as the general population. Patients treated with an anti-CD20 therapy for a longer period of time might be at a higher risk of COVID-19 and less than 20% generate an antibody response. Only age was related to severity.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3384-3395Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 European Academy of Neurology.
Références
Zhou P, Lou YX, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. https://doi.org/10.1038/s41586-020-2012-7
Sastre-Garriga J, Tintoré M, Montalban X. Keeping standards of multiple sclerosis care through the COVID-19 pandemic. Mult Scler J. 2020;26(10):1153-1156. https://doi.org/10.1177/1352458520931785
Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Dades actualitzades SARS-CoV-2. https://aquas.gencat.cat/ca/actualitat/ultimes-dades-coronavirus/. Published 2020. Accessed October 14, 2020.
Persson R, Lee S, Ulcickas Yood M, et al. Infections in patients diagnosed with multiple sclerosis: a multi-database study. Mult Scler Relat Disord. 2020;41:101982. https://doi.org/10.1016/j.msard.2020.101982
Celius EG. Infections in patients with multiple sclerosis: implications for disease-modifying therapy. Acta Neurol Scand. 2017;136:34-36. https://doi.org/10.1111/ane.12835
Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult Scler Relat Disord. 2020;43:102174. https://doi.org/10.1016/j.msard.2020.102174
Sormani MP, De Rossi N, Schiavetti I. Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis. SSRN Electronic Journal. http://doi.org/10.2139/ssrn.3631244.
Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020;43:102195. https://doi.org/10.1016/j.msard.2020.102195
Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-286. https://doi.org/10.1212/WNL.0000000000000560
Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020. https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition. Accessed June 3, 2020.
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. https://doi.org/10.1016/j.jbi.2019.103208
Agencia Tributaria Española. Estadística de los declarantes del IRPF de los mayores municipios por código postal: 2017: Estadística de los declarantes del Impuesto sobre la Renta de las Personas Físicas de los mayores municipios por código postal 2017. https://www.agenciatributaria.es/AEAT/Contenidos_Comunes/La_Agencia_Tributaria/Estadisticas/Publicaciones/sites/irpfCodPostal/2017/home.html. Published 2017. Accessed May 27, 2020.
U.S. National Cancer Institute (NCI). Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events (CTCAE) v5.0.; 2017. https://www.meddra.org/. Accessed June 4, 2020.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. https://doi.org/10.1001/jama.2020.2648
Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet (London, England). 2020;396(10250):535-544. https://doi.org/10.1016/S0140-6736(20)31483-5
Sormani MP. An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. 2020;19(6):481-482. https://doi.org/10.1016/S1474-4422(20)30147-2
Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77(9):1079. https://doi.org/10.1001/jamaneurol.2020.2581
Moss BP, Mahajan KR, Bermel RA, et al. Multiple sclerosis management during the COVID-19 pandemic. Mult Scler J. 2020;26(10):1163-1171. https://doi.org/10.1177/1352458520948231
Prieto-Alhambra D, Ballo E, Coma-Redon E, et al. Hospitalization and 30-day fatality in 121,263 COVID-19 outpatient cases. medRxiv. 2020. https://doi.org/10.1101/2020.05.04.20090050v1.
Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020;395(10228):931-934. https://doi.org/10.1016/S0140-6736(20)30567-5
Azar KMJ, Shen Z, Romanelli RJ, et al. Disparities in outcomes among COVID-19 patients in a large health care system in California. Health Aff (Millwood). 2020;39(7):1253-1262. https://doi.org/10.1377/hlthaff.2020.00598
Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95. https://doi.org/10.1016/j.ijid.2020.03.017
Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-688. https://doi.org/10.1056/NEJMoa0706383
Mitchell F. Vitamin-D and COVID-19: do deficient risk a poorer outcome? Lancet Diabetes Endocrinol. 2020;8:570. https://doi.org/10.1016/S2213-8587(20)30183-2
Berger JR, Brandstadter R, Bar-Or A. COVID-19 and MS disease-modifying therapies. Neurol Neuroimmunol Neuroinflammation. 2020;7(4):e761. https://doi.org/10.1212/nxi.0000000000000761
Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P, Porta-Etessam J, Pytel V, Matias-Guiu JA. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain. Mult Scler Relat Disord. 2020;42:102185. https://doi.org/10.1016/j.msard.2020.102185
Minotti C, Tirelli F, Barbieri E, Giaquinto C, Donà D. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review. J Infect. 2020;81(1):e61-e66. https://doi.org/10.1016/j.jinf.2020.04.026
Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184-191. https://doi.org/10.1001/jamaneurol.2019.3365
Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw open. 2018;1(7):e184169. https://doi.org/10.1001/jamanetworkopen.2018.4169
Meca-Lallana V, Aguirre C, Río B, Cardeñoso L, Alarcon T, Vivancos J. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. Mult Scler Relat Disord. 2020;44:102306. https://doi.org/10.1016/j.msard.2020.102306
Parrotta E, Kister I, Charvet L, et al. COVID-19 outcomes in MS. Neurol Neuroimmunol Neuroinflammation. 2020;7(5):e835. https://doi.org/10.1212/NXI.0000000000000835
Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases-case series from New York. N Engl J Med. 2020;383(1):85-88. https://doi.org/10.1056/nejmc2009567
Henry BM, De Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021-1028. https://doi.org/10.1515/cclm-2020-0369
Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1-5. https://doi.org/10.1038/s41591-020-0965-6
Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020;95(14):e1999-e2008. https://doi.org/10.1212/wnl.0000000000010380
Maillart E, Papeix C, Lubetzki C, Roux T, Pourcher V, Louapre C. Beyond COVID-19: do MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies? Mult Scler Relat Disord. 2020;46:102482. https://doi.org/10.1016/j.msard.2020.102482
Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020. 183(1)158-168.e14. https://doi.org/10.1101/2020.06.29.174888